Growth Hormone Receptor mRNA Expression in Non-Functioning and Somatotroph Pituitary Adenomas: Implications for Growth Hormone Substitution Therapy?[*]

Abstract

The use of growth hormone (GH) in patients with GH deficiency induced by pituitary adenoma is widely accepted, but the safety of this mitogenic hormone, particularly in patients with residual tumor after neurosurgery, continues to be a concern. Since the mitogenic potency of GH is dependent upon the presence of the GH receptor (GH-R) and the subsequent IGF-1/IGF receptor (IGF-1-R) system we investigated the expression of the members of the growth hormone cascade in endocrine inactive and GH-producing pituitary adenomas. Tissue specimens of 18 clinically non-functioning pituitary adenomas and 6 GH-producing adenomas were collected following transsphenoidal surgery while normal cadaver pituitary glands served as controls. After RNA extraction, semi-quantitative RT-PCR amplification with specific primers for GH, GH-R, IGF-1 and IGF-1-R was performed. Applying this sensitive RT-PCR based approach, GH-R expression was demonstrated in all normal pituitaries, most inactive adenomas (94 %), and the majority of GH-producing adenomas (66 %). Both IGF-1 and IGF-1-R mRNA was detectable in the majority of inactive (72 % and 77 %, respectively) and somatotrophic adenomas (83 % and 83 %). While IGF-1-R mRNA was expressed in all normal pituitary specimen studied, IGF-1 was detectable in only 55 % of them. In summary, expression of members of the GH-IGF-1 cascade could be demonstrated in a substantial subset of patients with non-functioning and GH-producing pituitary adenomas. These factors might serve as a substrate for the transduction of mitogenic effects of GH on remnant pituitary tumors during GH replacement therapy. Therefore, GH therapy should be carefully considered and patients on GH therapy kept under close observation.

Pituitary adenoma - growth hormone - growth hormone receptor - IGF1 - IGF1 receptor

References

• 1 Chan J M. et al . Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.  Science. 1998;  279 563-566
• 2 Ebersold M J. et al . Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas.  J Neurosurg. 1986;  64 713-719
• 3 Giustina A, Veldhuis J D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.  Endocr Rev. 1998;  19 717-797
• 4 Hankinson S E. et al . Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.  Lancet. 1998;  351 1393-1396
• 5 Khandwala H M. et al . The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.  Endocr Rev. 2000;  21 215-244
• 6 Kovacs K, Horvath E. Tumors of the pituitary gland. Hartmann WH, Sobin LH Atlas of Tumor Pathology, Second Series, Fascicle 21. Washington, D. C.; Armed Forces Institute of Pathology 1986
• 7 Melmed S. Acromegaly and cancer: not a problem?.  J Clin Endocrinol Metab. 2001;  86 2929-2934
• 8 Mertani H C. et al . Cellular localization of the growth hormone receptor/binding protein in the human anterior pituitary gland.  J Clin Endocrinol Metab. 1995;  80 3361-3367
• 9 Mindermann T, Wilson C B. Age-related and gender-related occurrence of pituitary adenomas.  Clin Endocrinol (Oxf). 1994;  41 359-364
• 10 Oomizu S. et al . Stimulatory effect of insulin-like growth factor I on proliferation of mouse pituitary cells in serum-free culture.  J Endocrinol. 1998;  157 53-62
• 11 Orme S M. et al . Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.  J Clin Endocrinol Metab. 1998;  83 2730-2734
• 12 Resnicoff M. et al . Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors.  Cancer Res. 1994;  54 2218-2222
• 13 Sassolas G. et al . Management of nonfunctioning pituitary adenomas.  Acta Endocrinol (Copenh). 1993;  129 21-26
• 14 Schwartz J. Intercellular communication in the anterior pituitary.  Endocr Rev. 2000;  21 488-513
• 15 van der Lely A J. et al . Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.  J Clin Endocrinol Metab. 2001;  86 478-481
• 16 Yamasaki H. et al . Binding and action of insulin-like growth factor I in pituitary tumor cells.  Endocrinology. 1991;  128 857-862
• 17 Yamashita S. et al . Insulin-like growth factor I regulates growth hormone secretion and messenger ribonucleic acid levels in human pituitary tumor cells.  J Clin Endocrinol Metab. 1986;  63 730-735
• 18 Zhu T. et al . Signal transduction via the growth hormone receptor.  Cell Signal. 2001;  13 599-616

1 This study was supported by a research grant awarded by the German Endocrine Society to F. B.